138 related articles for article (PubMed ID: 38131316)
1. Impact of a hospital sepsis management protocol on the selection of empirical antibiotics in infectious disease consultations.
Özden A; Dalgıç B; Demir M; Hazırolan G; Uzun Ö; Metan G
J Chemother; 2024 May; 36(3):190-197. PubMed ID: 38131316
[TBL] [Abstract][Full Text] [Related]
2. Cefoxitin versus carbapenems as definitive treatment for extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteremia in intensive care unit: a propensity-matched retrospective analysis.
Dequidt T; Bastian S; Nacher M; Breurec S; Carles M; Thiery G; Camous L; Tressieres B; Valette M; Pommier JD
Crit Care; 2023 Nov; 27(1):418. PubMed ID: 37915017
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes in patients with piperacillin/tazobactam-non-susceptible but ceftriaxone-susceptible E. coli or K. pneumoniae bloodstream infection.
Mourad A; Smith AG; Troy JD; Holland TL; Wrenn RH; Turner NA
J Antimicrob Chemother; 2024 Jun; 79(6):1456-1461. PubMed ID: 38708907
[TBL] [Abstract][Full Text] [Related]
4. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
[TBL] [Abstract][Full Text] [Related]
5. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
Ko JH; Lee NR; Joo EJ; Moon SY; Choi JK; Park DA; Peck KR
Eur J Clin Microbiol Infect Dis; 2018 Feb; 37(2):305-311. PubMed ID: 29177611
[TBL] [Abstract][Full Text] [Related]
6. Initial empirical antibiotics of non-carbapenems for ESBL-producing E. coli and K. pneumoniae bacteremia in children: a retrospective medical record review.
Park S; So H; Kim MN; Lee J
BMC Infect Dis; 2022 Nov; 22(1):866. PubMed ID: 36404302
[TBL] [Abstract][Full Text] [Related]
7. Win Ratio Analyses of Piperacillin-Tazobactam Versus Meropenem for Ceftriaxone-Nonsusceptible Escherichia coli or Klebsiella pneumoniae Bloodstream Infections: Post Hoc Insights From the MERINO Trial.
Hardy M; Harris PNA; Paterson DL; Chatfield MD; Mo Y;
Clin Infect Dis; 2024 Jun; 78(6):1482-1489. PubMed ID: 38306577
[TBL] [Abstract][Full Text] [Related]
8. Do Weekly Surveillance Cultures Contribute to Antibiotic Stewardship and Correlate with Outcome of HSCT in Children? A Multicenter Real-World Experience of 5 Years from the Indian Subcontinent.
Dhanya R; Agarwal RK; Ramprakash S; Trivedi D; Shah V; Bhat N; Reddy M; Elizabeth S; Batool A; Khalid S; Faulkner L
Transplant Cell Ther; 2022 Mar; 28(3):170.e1-170.e7. PubMed ID: 34936930
[TBL] [Abstract][Full Text] [Related]
9. Empirical carbapenems or piperacillin/tazobactam for infections in intensive care: An international retrospective cohort study.
Meier N; Munch MW; Granholm A; Perner A; Hertz FB; Venkatesh B; Hammond NE; Li Q; De Bus L; De Waele J; Kauzonas E; Sjövall F; Møller MH; Helleberg M
Acta Anaesthesiol Scand; 2024 Jul; 68(6):821-829. PubMed ID: 38549422
[TBL] [Abstract][Full Text] [Related]
10. Trend in Antibiotic Resistance of Extended-Spectrum Beta-Lactamase-Producing
Bayraktar B; Pelit S; Bulut ME; Aktaş E
Sisli Etfal Hastan Tip Bul; 2019; 53(1):70-75. PubMed ID: 33536830
[TBL] [Abstract][Full Text] [Related]
11. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
[TBL] [Abstract][Full Text] [Related]
12. Comparison of therapy with β-lactam/β-lactamase inhibitor combinations or carbapenems for bacteraemia of nonurinary source caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae.
Luo H; Xiao Y; Hang Y; Chen Y; Zhu H; Fang X; Cao X; Zou S; Hu X; Xiong J; Zhong Q; Hu L
Ann Clin Microbiol Antimicrob; 2021 Sep; 20(1):63. PubMed ID: 34488786
[TBL] [Abstract][Full Text] [Related]
13. Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales ("MERINO-3"): study protocol for a multicentre, open-label randomised non-inferiority trial.
Stewart AG; Harris PNA; Chatfield MD; Littleford R; Paterson DL
Trials; 2021 Apr; 22(1):301. PubMed ID: 33888139
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis.
Hoashi K; Hayama B; Suzuki M; Sakurai A; Takehana K; Enokida T; Takeda K; Ohkushi D; Doi Y; Harada S
Microbiol Spectr; 2022 Aug; 10(4):e0220622. PubMed ID: 35916524
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology, Risk Factors, and Clinical Outcomes of Bloodstream Infection due to Extended-Spectrum Beta-Lactamase-Producing
Liang T; Xu C; Cheng Q; Tang Y; Zeng H; Li X
Microb Drug Resist; 2021 Jun; 27(6):800-808. PubMed ID: 33232654
[No Abstract] [Full Text] [Related]
16. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome.
Kim SH; Kwon JC; Choi SM; Lee DG; Park SH; Choi JH; Yoo JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
Ann Hematol; 2013 Apr; 92(4):533-41. PubMed ID: 23161391
[TBL] [Abstract][Full Text] [Related]
17. Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals.
Kadri SS; Lai YL; Warner S; Strich JR; Babiker A; Ricotta EE; Demirkale CY; Dekker JP; Palmore TN; Rhee C; Klompas M; Hooper DC; Powers JH; Srinivasan A; Danner RL; Adjemian J;
Lancet Infect Dis; 2021 Feb; 21(2):241-251. PubMed ID: 32916100
[TBL] [Abstract][Full Text] [Related]
18. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
Han SB; Jung SW; Bae EY; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH; Kim HK; Park YJ
Microb Drug Resist; 2015 Apr; 21(2):244-51. PubMed ID: 25398058
[TBL] [Abstract][Full Text] [Related]
19. High burden of ESBL and carbapenemase-producing gram-negative bacteria in bloodstream infection patients at a tertiary care hospital in Addis Ababa, Ethiopia.
Beshah D; Desta AF; Woldemichael GB; Belachew EB; Derese SG; Zelelie TZ; Desalegn Z; Tessema TS; Gebreselasie S; Abebe T
PLoS One; 2023; 18(6):e0287453. PubMed ID: 37368908
[TBL] [Abstract][Full Text] [Related]
20. Increasing rates of extended-spectrum B-lactamase-producing Escherichia coli and Klebsiella pneumoniae in uncomplicated and complicated acute pyelonephritis and evaluation of empirical treatments based on culture results.
Kayaaslan B; Oktay Z; Hasanoglu I; Kalem AK; Eser F; Ayhan M; Guner R
Eur J Clin Microbiol Infect Dis; 2022 Mar; 41(3):421-430. PubMed ID: 34977996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
